San Francisco, 24 December 2024: The Report Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis), By Disease (Wet AMD, Dry AMD), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

The global age-related macular degeneration market size is expected to reach USD 17.99 billion by 2030, registering to grow at a CAGR of 8.2% from 2024 to 2030 according to a new report by Grand View Research, Inc. The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.’s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche’s Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2030 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company’s biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Request sample report of Age-related Macular Degeneration Market@ https://www.grandviewresearch.com/industry-analysis/age-related-macular-degeneration-market-report/request/rs1

The launch of new products, strong product pipeline, and increase in the prevalence rate of AMD are anticipated to be the major drivers for the market. As per the Population Reference Bureau, it is estimated that the population of Americans aged 65 and above will grow from 58 million in 2022 to 82 million by 2050, representing a 47% increase. The population in the U.S. is currently older than it has ever been.

Age-related Macular Degeneration Market Report Scope

 During the initial phase of the COVID-19 pandemic, the market for age-related macular degeneration was negatively impacted due to missed or delays in follow-up for AMD treatment leading to non-adherence to medications. For instance, in July 2020, Roche witnessed low growth in the sale of its AMD drug Lucentis to USD 401 million in the second quarter over the same period in the previous year.